Evercore ISI analyst Liisa Bayko maintained a Sell rating on AN2 Therapeutics, Inc. (ANTX – Research Report) yesterday and set a price target ...
If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common ...
11h
Investing News Network on MSNStem Cell Stocks: 10 Biggest NASDAQ Companies in 2025Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...
Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug ...
18h
Zacks.com on MSNVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Safi advancing manufactured human RBC (mRBC) program for acute bleeding and chronic transfusion indications This DoD award acceler ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results